Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: oramed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/12/2023 | $30.00 → $3.00 | Buy → Hold | Canaccord Genuity |
| 2/18/2022 | $20.00 | Overweight | Cantor Fitzgerald |
| 11/30/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
| 11/29/2021 | $17.00 → $32.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $20.00 → $35.00 | Buy | Aegis Capital |
| 7/29/2021 | $27.00 → $30.00 | Buy | Canaccord Genuity |
10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
10-Q - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
ARS - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)
NEW YORK, May 25, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, is pleased to provide the following Letter to Shareholders from Chief Executive Officer Nadav Kidron. Dear Shareholders, I'm excited to share with you significant milestones we have achieved over the past few months. Our oral delivery platform technology could apply to a range of proteins and disease modalities, and we expect over time to have a range of programs. We are currently advancing our two primary programs: oral insulin for diabetes and an oral COVID vaccine. We believe t
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
3 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
3 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)
NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market. Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned
NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board. Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes progra
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed's legal and corporate strategy affairs and provide strategic guidance to the executive team and Board of Directors. "We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer. Netanel's business-minded approach, legal acumen and strong operational skills will be instrumental to Oramed
SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13D/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
SC 13G/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. NovaBay Pharm
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oramed Pharmaceuticals (NASDAQ:ORMP) with a Neutral.
David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer.
As of Feb. 2, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here’s the latest list of major overbought players in this sector. PepGen Inc. (NASDAQ:PEPG) On Jan. 8, PepGen said First Patient was dosed in CONNECT1-EDO51 Phase 2
-8-K
An initial principal balance of $101,875,000.00; A senior lien for Oramed on substantially all assets of Scilex and its subsidiaries, subject to certain exclusions; 18-month maturity; Certain mandatory prepayment obligations tied to future equity or debt financings of Scilex (subject to certain limitations specified in the Note); Interest rate per annum is equal to the SOFR plus 8.5% (and subject to a SOFR floor of 4.0%); Repayment of principal in installments will commence on December 21, 2023, with a fixed portion of the principal balance required to be repaid in three month increments thereafter. If the Note is not repaid in full on or prior to March 21, 2024, an exit fee equal to
Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously
Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously
HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously
Aegis Capital reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $35.00 from $20.00 previously
Canaccord Genuity reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $30.00 from $27.00 previously
Aegis Capital reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $20.00 from $12.00 previously
Canaccord Genuity initiated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $27.00
National Securities Corporation initiated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $23.00
National Securities initiated coverage of Oramed Pharmaceuticals with a rating of Buy
NEW YORK, Oct. 7, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed"), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the execution of definitive agreements for the restructuring of a portion of its existing Senior Secured Promissory Note from Scilex Holding Company (NASDAQ:SCLX) ("Scilex"), a company focused on non-opioid pain management products. Key Highlights:Oramed, affiliates of Murchinson and 3i LP, entered into definitive agreements with Scilex for the purchase and sale of new tranche B senior secured convertible notes ("Notes") in the aggregate principal amount of $50 million (th
Stock Repurchase Program Scilex Senior Secured NotePhase 3 Oral Insulin Trial in USJV with Chinese Partner, HTITNEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. Dear Shareholders, In light of our recent announcement regarding Oramed's $20 million stock repurchase program, we believe this is an opportune moment to provide our shareholders with a comprehensive update on our activities and progress. As this development demonstrates our
NEW YORK, June 26, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (the "Company") (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months (the "Stock Buy Back Program"). The manner, timing and number of shares purchased will be at the
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has paid off the remaining balance of approx. $1,300,000 under the convertible debentures (the "Convertible Debentures") previously issued and sold to YA II PN, Ltd. ("Yorkville") in March 2023. Scilex has also voluntarily made an early payment in the aggregate amount of $15,000,000 under the senior secured promissory note (the "Oramed Note") issued to Oramed Pharmaceuticals Inc. (NASDAQ:
Initiating Phase 3 oral insulin trial in the United States under a new protocol JV with Chinese Partner, HTITScilex Senior Secured NotePeriTech Asset Purchase & Strategic Out-licensing NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you an update regarding Oramed. Despite the unexpected negative results we received for our U.S. based Phase 3 trial at the outset of last year, I am happy
SAN DIEGO, Sept. 22, 2023 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTC:SRNEQ, ", Sorrento", or ", Company", ))), a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company (NASDAQ:SCLX, ", Scilex", ))) of certain securities that Sorrento held in Scilex. Pursuant to that certain Stock Purchase Agreement entered into on September 21, 2023, between Scilex and Sorrento, Scilex, through its wholly-owned subsidiary, acquired (i) all of the shares of Scilex common stock owned by Sorrento (other than suc
18-month loan with interest rate of SOFR plus 8.5% Oramed receives warrants to purchase up to 17 million shares of Scilex common stock The Senior Secured Note with Scilex replaces Oramed's previously announced Stock Purchase Agreement and DIP Term Loan with Sorrento TherapeuticsNEW YORK, Sept. 21, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE:ORMP) today announced that on September 21, 2023, Oramed and Scilex Holding Company ("Scilex") entered into a Securities Purchase Agreement pursuant to which Scilex issued a Senior Secured Promissory Note (the "Note") to Oramed. The Note is the culmination of Scilex's assumption of Sorrento Therapeutics Inc.'s ("Sorrento") approx
PALO ALTO, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))). Pursuant to that certain Stock Purchase Agreement entered into on September [21], 2023, between Scilex and Sorrento, Scilex, through its wholly-owned subsidiary, acquired (i) all of the shares of Scilex common stock owned by Sorrento (other than such shares held in a
PALO ALTO, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC:SRNEQ, "Sorrento"))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP, "Oramed"))) and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer (as defined below) (the "Securities Transfer Term Sheet") (which the official committee of unsecured creditors and th
JV will have global marketing rights to oral drug delivery technologyHTIT to invest $60 million, Oramed to invest $10 million into JVHTIT to provide a supply agreement for oral insulin capsule JV to advance registration of oral insulin in the United States and other countriesNEW YORK, Aug. 2, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com) announced today that it has signed a non-binding term sheet with Hefei Tianhui Biotech Co., Ltd. ("HTIT") to establish a joint venture ("JV") based on Oramed's oral drug delivery technology. The proposed JV would focus on the development and worldwide commercialization of innovative products based on Oramed's or